ArticlePulmonary therapy2026
Sequential Pleural Fluid and Serum Biomarker Measurements in Patients Undergoing Medical Thoracoscopy for Persistently Undiagnosed Pleural Effusion: A Pilot Study from a TB-Endemic Tertiary Centre.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06159179 (Medical Thoracoscopy for Undiagnosed Transudative and Exudative Pleural Effusion), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Medical Thoracoscopy for Undiagnosed Transudative and Exudative Pleural Effusion
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPleural effusion remains diagnostically challenging when standard thoracentesis does not establish an aetiology. This pilot analysis described sequential biomarker measurements in patients proceeding to medical thoracoscopy and explored their associations and discrimination across final diagnostic classifications.
methodsProspectively collected data from a single-centre tertiary referral cohort were analysed. Pleural-fluid adenosine deaminase (ADA) and serum complement components 3 and 4 (C3 and C4) were obtained on day 1, whereas pleural-fluid cancer antigen 125 (CA125) and lactate dehydrogenase (LDH) were obtained at the day 7/thoracoscopy evaluation. Final classifications were based on a composite reference standard integrating thoracoscopy, histopathology, microbiology, cytology, imaging, and clinical follow-up. Analyses were exploratory.
resultsAmongst 75 patients, 6 (8.0%) were classified as tuberculous pleural effusion (TB-PE), 33 (44.0%) as malignant pleural effusion (MPE) and 36 (48.0%) as other non-tuberculous, non-malignant pleural effusions. ADA differed across groups (Kruskal-Wallis P = 0.002; Benjamini-Hochberg q = 0.010) and showed exploratory discrimination for TB-PE (area under the curve [AUC] 0.934; bootstrap 95% confidence interval [CI] 0.855-0.995). At the conventional ≥ 40 U/L threshold, sensitivity was 83.3%, specificity 93.4%, positive predictive value (PPV) 55.6%, negative predictive value (NPV) 98.3%, positive likelihood ratio (LR+) 12.7, and negative likelihood ratio (LR-) 0.18. CA125, LDH, C3 and C4 did not show significant omnibus group differences after reanalysis. In a post hoc sensitivity analysis excluding 26 patients retained as non-specific pleuritis (n = 49), ADA remained significantly different across groups (P = 0.004; q = 0.022).
conclusionsIn this selected thoracoscopy cohort, day 1 pleural-fluid ADA showed the clearest exploratory signal, including after exclusion of non-specific pleuritis, but estimates were based on only six TB-PE cases and do not establish stand-alone utility or a role in avoiding thoracoscopy. The remaining biomarkers showed no robust aetiology-specific signal.
trial registrationClinicalTrials.gov NCT06159179.
Indexed as
Identifiers
42909836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.